

# Gopala K Rangan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3423554/publications.pdf>

Version: 2024-02-01

66  
papers

1,173  
citations

516561

16  
h-index

414303

32  
g-index

66  
all docs

66  
docs citations

66  
times ranked

1606  
citing authors

#	ARTICLE	IF	CITATIONS
1	Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report. CKJ: Clinical Kidney Journal, 2022, 15, 407-416.	1.4	3
2	Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease. , 2022, 1, .		17
3	Recurrent hyperparathyroidism presenting as spinal cord compression. Kidney International, 2022, 101, 834.	2.6	0
4	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€™ Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. American Journal of Kidney Diseases, 2021, 77, 255-263.	2.1	21
5	Effect of Reducing Ataxia-Telangiectasia Mutated (ATM) in Experimental Autosomal Dominant Polycystic Kidney Disease. Cells, 2021, 10, 532.	1.8	8
6	Long-term dietary nitrate supplementation does not reduce renal cyst growth in experimental autosomal dominant polycystic kidney disease. PLoS ONE, 2021, 16, e0248400.	1.1	2
7	Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD. Kidney International Reports, 2021, 6, 1032-1040.	0.4	0
8	Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review. PLoS ONE, 2021, 16, e0252479.	1.1	4
9	Up-Regulation of DNA Damage Response Signaling in Autosomal Dominant Polycystic Kidney Disease. American Journal of Pathology, 2021, 191, 902-920.	1.9	10
10	Possible role of the mitochondrial genome in the pathogenesis of autosomal dominant polycystic kidney disease. Nephrology, 2021, 26, 920-930.	0.7	1
11	Role of DNA-Dependent Protein Kinase in Mediating Cyst Growth in Autosomal Dominant Polycystic Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 10512.	1.8	3
12	Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of whole-genome sequencing. European Journal of Human Genetics, 2021, 29, 760-770.	1.4	20
13	Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease. Journal of Cardiovascular Development and Disease, 2021, 8, 144.	0.8	0
14	Clinical characteristics and outcomes of hyponatraemia associated with oral water intake in adults: a systematic review. BMJ Open, 2021, 11, e046539.	0.8	13
15	Role of cyclin-dependent kinase 2 in the progression of mouse juvenile cystic kidney disease. Laboratory Investigation, 2020, 100, 696-711.	1.7	6
16	â€™A sword of Damoclesâ€™™: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open, 2020, 10, e038005.	0.8	5
17	Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease. Nutrients, 2020, 12, 3376.	1.7	1
18	Current and emerging treatment options to prevent renal failure due to autosomal dominant polycystic kidney disease. Expert Opinion on Orphan Drugs, 2020, 8, 285-302.	0.5	3

#	ARTICLE	IF	CITATIONS
19	RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapid Disease) Tj ETQq1 1 0.784314 rgBT /Overlock 1071 retrospective cohort study. BMJ Open, 2020, 10, e034103.	0.8	5
20	Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. American Journal of Kidney Diseases, 2020, 76, 361-373.	2.1	23
21	Effects of Allopurinol on the Progression of Chronic Kidney Disease. New England Journal of Medicine, 2020, 382, 2504-2513.	13.9	281
22	Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. American Journal of Kidney Diseases, 2020, 76, 213-223.	2.1	16
23	<p>Regression of Peritubular Capillaries Coincides with Angiogenesis and Renal Cyst Growth in Experimental Polycystic Kidney Disease</p>. International Journal of Nephrology and Renovascular Disease, 2020, Volume 13, 53-64.	0.8	5
24	Patient needs and priorities for patient navigator programmes in chronic kidney disease: a workshop report. BMJ Open, 2020, 10, e040617.	0.8	14
25	Adenine Phosphoribosyltransferase Deficiency: A Potentially Reversible Cause of CKD. Kidney International Reports, 2019, 4, 1161-1170.	0.4	12
26	Identifying patientâ€™important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology, 2019, 24, 1214-1224.	0.7	20
27	The role of DNA damage as a therapeutic target in autosomal dominant polycystic kidney disease. Expert Reviews in Molecular Medicine, 2019, 21, e6.	1.6	9
28	Increased water intake reduces long-term renal and cardiovascular disease progression in experimental polycystic kidney disease. PLoS ONE, 2019, 14, e0209186.	1.1	16
29	Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis. Experimental Biology and Medicine, 2018, 243, 428-436.	1.1	11
30	Relative Validity of a Beverage Frequency Questionnaire Used to Assess Fluid Intake in the Autosomal Dominant Polycystic Kidney Disease Population. Nutrients, 2018, 10, 1051.	1.7	1
31	Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open, 2018, 8, e018794.	0.8	60
32	Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?. World Journal of Nephrology, 2018, 7, 51-57.	0.8	5
33	Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963â€™2014). Population Health Metrics, 2017, 15, 7.	1.3	15
34	Standardised Outcomes in Nephrologyâ€™Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials, 2017, 18, 560.	0.7	20
35	A systematic review to determine the most effective interventions to increase water intake. Nephrology, 2016, 21, 860-869.	0.7	11
36	Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease. PLoS ONE, 2016, 11, e0164193.	1.1	15

#	ARTICLE	IF	CITATIONS
37	Constitutive renal Rel/nuclear factor- $\beta$ expression in Lewis polycystic kidney disease rats. World Journal of Nephrology, 2016, 5, 339.	0.8	16
38	A protocol for the identification and validation of novel genetic causes of kidney disease. BMC Nephrology, 2015, 16, 152.	0.8	8
39	Effects of pyrrolidine dithiocarbamate on proliferation and nuclear factor- $\beta$ activity in autosomal dominant polycystic kidney disease cells. BMC Nephrology, 2015, 16, 212.	0.8	8
40	Autosomal Dominant Polycystic Kidney Disease: A Path Forward. Seminars in Nephrology, 2015, 35, 524-537.	0.6	18
41	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetics and Genetic Counseling. Seminars in Nephrology, 2015, 35, 550-556.e1.	0.6	5
42	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Screening for Polycystic Kidney Disease. Seminars in Nephrology, 2015, 35, 557-564.e6.	0.6	7
43	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetic Testing for Diagnosis. Seminars in Nephrology, 2015, 35, 545-549.e2.	0.6	10
44	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Monitoring Disease Progression. Seminars in Nephrology, 2015, 35, 565-571.e18.	0.6	4
45	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Diet and Lifestyle Management. Seminars in Nephrology, 2015, 35, 572-581.e17.	0.6	17
46	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management. Seminars in Nephrology, 2015, 35, 582-589.e17.	0.6	9
47	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Psychosocial Care. Seminars in Nephrology, 2015, 35, 590-594.e5.	0.6	2
48	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of End-Stage Kidney Disease. Seminars in Nephrology, 2015, 35, 595-602.e12.	0.6	3
49	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Renal Stone Disease. Seminars in Nephrology, 2015, 35, 603-606.e3.	0.6	11
50	KHA-CARI Autosomal Dominant Kidney Disease Guideline: Management of Chronic Pain. Seminars in Nephrology, 2015, 35, 607-611.e3.	0.6	6
51	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Intracranial Aneurysms. Seminars in Nephrology, 2015, 35, 612-617.e20.	0.6	17
52	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Polycystic Liver Disease. Seminars in Nephrology, 2015, 35, 618-622.e5.	0.6	14
53	Levels of haloacetic acids in tap water in an urban Australian city and its relevance to autosomal dominant polycystic kidney disease. Kidney International, 2014, 85, 1471.	2.6	1
54	Progression of polycystic kidney disease—a lack of progress?. Nature Reviews Nephrology, 2014, 10, 489-491.	4.1	1

#	ARTICLE	IF	CITATIONS
55	Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. <i>Nephrology</i> , 2013, 18, 317-330.	0.7	65
56	Chronic effects of dietary vitamin D deficiency without increased calcium supplementation on the progression of experimental polycystic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, F574-F582.	1.3	14
57	Autosomal dominant polycystic kidney disease (ADPKD) is associated with coronary arterial dilatation in end-stage renal failure patients. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 41-43.	1.4	1
58	NF-kappaB signalling in chronic kidney disease. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 3496.	3.0	71
59	Therapeutic role of sirolimus in non-transplant kidney disease. , 2009, 123, 187-206.		15
60	Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2175-2182.	0.4	38
61	Temporal Relationship between Renal Cyst Development, Hypertension and Cardiac Hypertrophy in a New Rat Model of Autosomal Recessive Polycystic Kidney Disease. <i>Kidney and Blood Pressure Research</i> , 2007, 30, 129-144.	0.9	77
62	Sirolimus-Associated Proteinuria and Renal Dysfunction. <i>Drug Safety</i> , 2006, 29, 1153-1161.	1.4	45
63	Effect of Nephrotoxins on Tubulointerstitial Injury and NF- $\kappa$ B Activation in Adriamycin Nephropathy. <i>Renal Failure</i> , 2005, 27, 609-614.	0.8	0
64	Dietary Quercetin Augments Activator Protein-1 and Does Not Reduce Nuclear Factor- $\kappa$ B in the Renal Cortex of Rats with Established Chronic Glomerular Disease. <i>Nephron</i> , 2002, 90, 313-319.	0.9	29
65	Mild gentamicin nephrotoxicity reduces the progression of chronic adriamycin nephrosis. <i>Nephrology</i> , 1998, 4, 57-64.	0.7	5
66	Mild gentamicin nephrotoxicity reduces the progression of chronic adriamycin nephrosis. <i>Nephrology</i> , 1998, 4, 57-64.	0.7	0